ltt462
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 15, 2016 (NCT02711345)
Timeline
Indications
Mechanism of action
- MAP kinase ERK1INHIBITOR
MAPK3 inhibitor
- MAP kinase ERK2INHIBITOR
MAPK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ltt462
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04417621 | Phase 2 | Jul 13, 2020 | Novartis |
| NCT04294160 | Phase 1 | May 26, 2020 | Novartis |
| NCT02974725 | Phase 1 | Feb 24, 2017 | Novartis |
| NCT02711345 | Phase 1 | Apr 15, 2016 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 2 | 2016 |
1 organizations
Page 1 / 1